Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

With MANKIND's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 37.633385
debtToEquity 53.892000
earningsGrowth 0.048000
revenueGrowth 0.104000
grossMargins 0.702480
operatingMargins 0.195340
trailingEps 43.140000
forwardEps 59.627910

MANKIND's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for MANKIND's financial performance.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

Mankind Pharma Limited's price has often been near the lower end of the projected range. This ongoing trend suggests that investor confidence might be waning, and the stock could face challenges in gaining upward momentum.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


MANKIND has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as MANKIND is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.